Fig. 2: Thermostability and binding affinity of nanobody mutants with pAcF incorporated. | Communications Biology

Fig. 2: Thermostability and binding affinity of nanobody mutants with pAcF incorporated.

From: Noncanonical amino acid-aided synthesis of anti-PD-L1 bispecific nanobody for colon cancer immunotherapy

Fig. 2: Thermostability and binding affinity of nanobody mutants with pAcF incorporated.

A The effect of TSDV mutation on pAcF-incorporated sfGFP expression; Treated, sfGFP2TAG expression in presence of pAcF in cell growth medium; Control, sfGFP2TAG expression in absence of pAcF in cell growth medium; GFP(WT), wild-type sfGFP expression. B Expression of sfGFP with pAcF incorporated by pCNFRS and pCNFRS-TSDV; C The melting temperatures of PV2 and PV3 nanobody mutants. Melting temperatures of PV2 and PV3 variants were measured using differential scanning fluorimetry. (Note: The data in the figure are x ± SD, n = 5 independent experiment; a significant difference from the WT group, *: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001); D Binding affinity of PV2 and PV3 nanobody mutants determined by ELISA (n = 3 independent experiment); E, The binding constant of PV2 and PV3 nanobody mutants.

Back to article page